3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Phase 2
1
Phase 1
1
Status
Completed
5
Terminated
3
Unknown
1
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
305
Carcinoma, Non-Small-Cell Lung
287
Colorectal Neoplasms
159
Prostatic Neoplasms
158
Carcinoma, Hepatocellular
144
Neoplasms
137
Leukemia, Myeloid, Acute
131
Lung Neoplasms
117
Squamous Cell Carcinoma of Head and Neck
108
Multiple Myeloma
104
Triple Negative Breast Neoplasms
102
Recurrence
101
Pancreatic Neoplasms
96
Stomach Neoplasms
94
Ovarian Neoplasms
89
Neoplasm Metastasis
87
Lymphoma, Large B-Cell, Diffuse
81
Sarcoma
70
Esophageal Neoplasms
68
Uterine Cervical Neoplasms
67
Precursor Cell Lymphoblastic Leukemia-Lymphoma
67
Melanoma
67
Brain Neoplasms
67
Rectal Neoplasms
64
Head and Neck Neoplasms
62
Glioblastoma
60
Carcinoma, Renal Cell
58
Myelodysplastic Syndromes
55
Lymphoma
55
Esophageal Squamous Cell Carcinoma
54
Interventions
pembrolizumab
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Recruiting
×
Colitis, Ulcerative
×
Clear all
NCT07223424
2026-04-16
PSI-Immune
University of Pittsburgh
Phase 2
Recruiting
880 enrolled